These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35076865)

  • 1. Stromal Changes are Associated with High P4HA2 Expression in Ductal Carcinoma in Situ of the Breast.
    Agahozo MC; van Bockstal M; Westenend PJ; Galant C; Lambein K; Reisenbichler E; Sinke R; Wong S; van Deurzen CHM
    J Mammary Gland Biol Neoplasia; 2021 Dec; 26(4):367-375. PubMed ID: 35076865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast.
    Van Bockstal M; Lambein K; Gevaert O; De Wever O; Praet M; Cocquyt V; Van den Broecke R; Braems G; Denys H; Libbrecht L
    Histopathology; 2013 Oct; 63(4):520-33. PubMed ID: 23889174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).
    Toss MS; Miligy IM; Gorringe KL; AlKawaz A; Khout H; Ellis IO; Green AR; Rakha EA
    Br J Cancer; 2018 Dec; 119(12):1518-1526. PubMed ID: 30410060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dichotomous histopathological assessment of ductal carcinoma in situ of the breast results in substantial interobserver concordance.
    Van Bockstal M; Baldewijns M; Colpaert C; Dano H; Floris G; Galant C; Lambein K; Peeters D; Van Renterghem S; Van Rompuy AS; Verbeke S; Verschuere S; Van Dorpe J
    Histopathology; 2018 Dec; 73(6):923-932. PubMed ID: 30168167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.
    Sharma M; Beck AH; Webster JA; Espinosa I; Montgomery K; Varma S; van de Rijn M; Jensen KC; West RB
    Breast Cancer Res Treat; 2010 Sep; 123(2):397-404. PubMed ID: 19949854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune response and stromal changes in ductal carcinoma in situ of the breast are subtype dependent.
    Agahozo MC; Westenend PJ; van Bockstal MR; Hansum T; Giang J; Matlung SE; van Deurzen CHM
    Mod Pathol; 2020 Sep; 33(9):1773-1782. PubMed ID: 32341499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variability in grading of ductal carcinoma in situ among an international group of pathologists.
    van Seijen M; Jóźwiak K; Pinder SE; Hall A; Krishnamurthy S; Thomas JS; Collins LC; Bijron J; Bart J; Cohen D; Ng W; Bouybayoune I; Stobart H; Hudecek J; Schaapveld M; Thompson A; Lips EH; Wesseling J;
    J Pathol Clin Res; 2021 May; 7(3):233-242. PubMed ID: 33620141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.
    Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR
    Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast.
    Van Bockstal M; Lambein K; Smeets A; Slembrouck L; Neven P; Nevelsteen I; Weltens C; Van Limbergen E; Christiaens MR; Van Ongeval C; Wildiers H; Libbrecht L; Floris G
    Eur J Surg Oncol; 2019 Apr; 45(4):550-559. PubMed ID: 30454971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of stromal immune microenvironment in the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer.
    Niwińska A; Olszewski WP
    Breast Cancer Res; 2021 Dec; 23(1):118. PubMed ID: 34952631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Changes of fibroblast immunophenotype and their clinical significance in stromal remodeling of breast tumors].
    Hua X; Huang X; Liao Z; Xian Q; Yu L
    Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):834-8. PubMed ID: 25620480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphological intratumor heterogeneity in ductal carcinoma in situ of the breast.
    Stanciu-Pop C; Nollevaux MC; Berlière M; Duhoux FP; Fellah L; Galant C; Van Bockstal MR
    Virchows Arch; 2021 Jul; 479(1):33-43. PubMed ID: 33502600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration.
    Osuala KO; Sameni M; Shah S; Aggarwal N; Simonait ML; Franco OE; Hong Y; Hayward SW; Behbod F; Mattingly RR; Sloane BF
    BMC Cancer; 2015 Aug; 15():584. PubMed ID: 26268945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does thymidine phosphorylase correlate with angiogenesis in intraductal carcinoma of the breast?
    Erkus M; Meteoglu I; Culhaci N; Meydan N; Erdogdu I
    Saudi Med J; 2006 Sep; 27(9):1329-33. PubMed ID: 16951768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Collagen Organization in Relation to Ductal Carcinoma
    Sprague BL; Vacek PM; Mulrow SE; Evans MF; Trentham-Dietz A; Herschorn SD; James TA; Surachaicharn N; Keikhosravi A; Eliceiri KW; Weaver DL; Conklin MW
    Cancer Epidemiol Biomarkers Prev; 2021 Jan; 30(1):80-88. PubMed ID: 33082201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour-infiltrating lymphocytes in ductal carcinoma in situ (DCIS)-assessment with three different methodologies and correlation with Oncotype DX DCIS Score.
    Komforti M; Badve SS; Harmon B; Lo Y; Fineberg S
    Histopathology; 2020 Nov; 77(5):749-759. PubMed ID: 32557780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk.
    Almekinders MM; Bismeijer T; Kumar T; Yang F; Thijssen B; van der Linden R; van Rooijen C; Vonk S; Sun B; Parra Cuentas ER; Wistuba II; Krishnamurthy S; Visser LL; Seignette IM; Hofland I; Sanders J; Broeks A; Love JK; Menegaz B; Wessels L; Thompson AM; de Visser KE; Hooijberg E; Lips E; Futreal A; Wesseling J;
    Br J Cancer; 2022 Oct; 127(7):1201-1213. PubMed ID: 35768550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recognizing breast ductal carcinoma in situ on fine-needle aspiration: a diagnostic dilemma.
    Guo HQ; Zhang ZH; Zhao H; Zhao LL; Pan QJ
    Diagn Cytopathol; 2013 Aug; 41(8):710-5. PubMed ID: 23729369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ColXα1 is a stromal component that colocalizes with elastin in the breast tumor extracellular matrix.
    Wang Y; Lu S; Xiong J; Singh K; Hui Y; Zhao C; Brodsky AS; Yang D; Jolly G; Ouseph M; Schorl C; DeLellis RA; Resnick MB
    J Pathol Clin Res; 2019 Jan; 5(1):40-52. PubMed ID: 30207088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
    Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.